AGP Executive Report
Last update: an hour agoEbola Preparedness: WHO praised Uganda’s response to a Bundibugyo Ebola outbreak linked to the DRC, urging continued vigilance and cross-border cooperation as labs and patient discharges support containment. Clinical Trial Watch: The EMNERGIZE phase 3 trial is recruiting for empasiprubart, a complement C2 inhibitor, for adults with active CIDP—targeting immune-driven nerve damage. Hematology Updates: EHA 2026 data highlights mosunetuzumab plus lenalidomide in follicular lymphoma, while separate reports cover FDA review progress for ozekibart in chondrosarcoma and AK117 combos in untreated AML. Public Health & Equity: Britain’s disability benefit milestone shows PIP claims topping 4 million, with mental health now driving over a third of claims—plus a rise in “treatable” minor ailments. Infection Control Guidance: WHO experts tackled Andes hantavirus isolation rules, focusing on how to safely stop spread in a rare person-to-person transmission scenario. Healthy Cities (EU): Ireland’s Carlow, Cork and Waterford join WHO’s European Healthy Cities network, reinforcing health, equity and sustainability in local governance. Sports Tourism & Fitness: Spain’s Canary Islands are booming with elite sports tourism, as athletes chase year-round training conditions. Nature & Wellbeing: Britain’s Peacock butterfly wins a national public vote, spotlighting pollinator-friendly habitats.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
